Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Theraclone reports Phase IIa data for anti-flu mAb

Theraclone Sciences Inc. (Seattle, Wash.) said a single dose of TCN-032 given 24 hours after viral inoculation missed the primary endpoint of reducing

Read the full 239 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE